Overall Regulatory Guidance for a new autoinjector

A start-up medical device company developing novel autoinjector technology sought Chimera’s general guidance on pharmaceutical requirements for the development and registration of their first demonstration product which was delivered by subcutaneous injection. Chimera participated in this project from the pre-IND phase through NDA submission and approval by providing advice at all stages of the development of this novel product.